|
12.12.2024 14:37:53
|
Trevi Reports Positive Outcome From Sample Size Re-estimation For Phase 2b CORAL Study; Stock Up
(RTTNews) - Trevi Therapeutics, Inc. (TRVI) Thursday reported positive outcome from sample size re-estimation for the ongoing Phase 2b CORAL trial in patients with idiopathic pulmonary fibrosis (IPF) who have chronic cough. The clinical-stage biopharmaceutical company's shares were surging more than 80 percent in pre-market.
Based on the Sample size re-estimation (SSRE), a method that allows to change the sample size of a clinical trial during its conduct, the current sample size of 160 is not required to change. The study has already reached 75 percent enrollment.
The company continues to expect topline data from the study in the first half of 2025.
Trevi stock had closed at $2.49, down 7.09 percent on Wednesday. It has traded in the range of $2.36 - $2.73 in the last 1 year.
Analysen zu Trevi Therapeutics Inc Registered Shs
Jahresrückblick & Jahresausblick 2024/2025 – Wall Street Live mit Tim Schäfer
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Trevi Therapeutics Inc Registered Shs | 4.00 | -1.48% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Vorweihnachtliche Zurückhaltung: SMI schlussendlich im Plus -- DAX geht schwächer aus dem HandelDer heimische Aktienmarkt schloss am Montag im Plus, wohingegen sich der deutsche Aktienmarkt abwärts bewegte.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |